Nitrogen In R Patents (Class 514/626)
-
Patent number: 7045549Abstract: Methods are provided for use in treating humans suffering from irritable bowel syndrome. In the subject methods, an effective amount of a nerve-acting agent, e.g., lidocaine, topiramate, mexiletine and gabapentin, etc., is administered to a human suffering from irritable bowel syndrome. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods.Type: GrantFiled: November 8, 2002Date of Patent: May 16, 2006Assignee: The Board of Trustees of the Leland Stanford Jr. UniversityInventors: Raymond R. Gaeta, Lynn Cintron
-
Patent number: 6963010Abstract: The disclosed invention provides new polyamine analogs and derivatives containing a hydrophobic region and a polyamine region as well as methods and compositions for their use.Type: GrantFiled: January 8, 2002Date of Patent: November 8, 2005Assignee: MediQuest Therapeutics, Inc.Inventors: Mark R. Burns, Gerard F. Graminski
-
Patent number: 6933320Abstract: An antitumor combination comprising a stilbene derivative and an anticancer compound selected from the group consisting of taxanes, alkylating agents, antimetabolites, vinca alkaloids, platinum compounds, epidophylloptoxins, and antibiotics as the active ingredients is provided. Methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like are also provided.Type: GrantFiled: March 15, 2002Date of Patent: August 23, 2005Assignee: Aventis Pharma S. A.Inventor: Marie-Christine Bissery
-
Patent number: 6900203Abstract: (R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: wherein R1, R2, and R4 are independently selected from —H or —F, at least one of R1, R2, and R4 is —F, and R3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed.Type: GrantFiled: July 8, 2002Date of Patent: May 31, 2005Assignee: Polium Technologies, Inc.Inventors: Hamilton J. Lenox, Elena Terentieva, Mikhail Y. Gololobov
-
Patent number: 6897209Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula (Y)m-A-NHR)k can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: August 22, 2003Date of Patent: May 24, 2005Assignee: GE Healthcare LimitedInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
-
Patent number: 6894078Abstract: A method for applying a topical anesthetic to an area of skin comprising the steps of a) incorporating an anesthetic in a lipophilic base into a volatile solvent, to form a homogeneous solution; b) applying the homogeneous solution into the area of skin to be treated; and c) evaporating the volatile solvent from the homogeneous solution; wherein the volatile solvent is present in the formulation in amounts between 40-80%; and wherein said topical anesthetic rapidly penetrates the skin surface at said skin, leaving a cooling sensation on the skin. The topical anesthetic formulation contains a penetrating enhancer carrier that markedly enhances the delivery of the anesthetic across human skin without altering the acceptable delivery rate of the anesthetic that needs to be delivered through the skin and leaves a cooling sensation on the skin.Type: GrantFiled: September 17, 2001Date of Patent: May 17, 2005Inventor: James G. Castillo
-
Patent number: 6890898Abstract: The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.Type: GrantFiled: July 3, 2002Date of Patent: May 10, 2005Assignees: Trustees of Tufts College, 1149336 Ontario Inc., New England Medical Center Hospitals, Inc.Inventors: William W. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 6881756Abstract: The present invention relates to a method for reducing inflammation in the skin and/or treating inflammatory skin disorders, pain, or pruritis by topically applying a composition comprising totarol or a pharmaceutically-acceptable ester thereof.Type: GrantFiled: September 17, 2002Date of Patent: April 19, 2005Assignee: Johnson & Johnson Consumer Companies, Inc.Inventor: Gerard J. Gendimenico
-
Patent number: 6855668Abstract: Methods and products for inhibiting growth of fungus and fungal disease on a plant. Methods comprise contacting at least a portion of a plant or plant seed together with a fungicidal composition comprising a fungicidal carboxamide. Products comprise any of leaves, crowns, roots, stolons, seed, seedlings, sod, and any combination thereof, treated with a fungicidal carboxamide. Preferred pathogens are of the genus Colletotrichum, preferred disease is anthracnose, preferred fungicides are carboxamides, and preferred plants are turfgrass.Type: GrantFiled: January 7, 2003Date of Patent: February 15, 2005Assignee: Board of Trustees of University of ArkansasInventor: Eugene A. Milus
-
Patent number: 6835388Abstract: A local anesthetic is used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for using a catheter to pertubate the fallopian tubes to reduce dysmenorrhoea and premenstrual syndrome symptoms in a woman with the pharmaceutical composition that is intended to reach and exert an effect in the peritoneal cavity.Type: GrantFiled: August 2, 2002Date of Patent: December 28, 2004Assignee: Org. Nr. 556599-4968Inventor: Greta Edelstam
-
Patent number: 6835846Abstract: The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: where n denotes an integer of 1 to 11, and 1 denotes an integer of 1 to 16, the aliphatic compound being an optical isomer of the (2R,3S,2′S) configuration when the 8-position thereof is a double bond, or an optical isomer of the (2S,3R,2′RS) configuration when the 8-position is a single bond; methods for producing the compound or pharmacologically acceptable salts thereof; and uses of the compound in the treatment of cardiovascular diseases (e.g. arteriosclerosis, cardiac diseases), cancer, rheumatism, diabetic retinopathy, and respiratory diseases.Type: GrantFiled: April 11, 2003Date of Patent: December 28, 2004Assignee: Maruha CorporationInventors: Tadakazu Tamai, Masazumi Nishikawa, Kenji Mori
-
Publication number: 20040260099Abstract: Novel prodrugs of amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and diseases associated with altered glycosphingolipid levels.Type: ApplicationFiled: April 15, 2004Publication date: December 23, 2004Applicant: The Regents of the University of MichiganInventor: James A. Shayman
-
Patent number: 6833377Abstract: A method of potentiating the activity of a drug which affects the central nervous system. (CNS) comprising systemically administrating to a subject said drug together with an effective amount of a compound which affects peripheral chemoreceptors and, optionally, with an effective amount of a stimulator of osmoreceptors. Also disclosed are pharmaceutical compositions for systemic administration comprising a CNS drug together with the aforementioned compounds.Type: GrantFiled: February 5, 2001Date of Patent: December 21, 2004Assignee: Gevys Pharmaceuticals Ltd.Inventor: Sergey Serdyuk
-
Patent number: 6825203Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.Type: GrantFiled: April 27, 2001Date of Patent: November 30, 2004Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gavril Pasternak, Yuri Kolesnikov
-
Patent number: 6803357Abstract: The present invention provides methods and compositions for modification and regulation of GLP 1 metabolism, glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions described herein are high-affinity boronyl and non-boronyl peptidomimetic inhibitors of DPIV.Type: GrantFiled: January 5, 2001Date of Patent: October 12, 2004Assignees: New England Medical Center Hospitals, Inc., Trustees of Tufts College, 1149336 Ontario Inc.Inventors: William A. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 6790855Abstract: Many chemical and pharmaceutical compositions are known to produce antinociceptive effects that are helpful in relieving pain and inflammation. Both opioids and local anesthetics serve an important function in providing peripheral pain relief. Topical administration of pain-relieving drugs to the periphery offers important advantages over systemic or local, non-topical administration. The present invention provides topical pharmaceutical compositions, formulated with at least one local anesthetic and at least one opioid analgesic in a topical excipient. The present invention also provides methods for relieving pain in a subject through topical administration of the pharmaceutical composition in an amount and a duration sufficient to synergistically potentiate an antinociceptive response. Synergistic potentiation of analgesia through topical administration of a local anesthetic/opioid pharmaceutical composition provides a new and improved approach to peripheral pain management.Type: GrantFiled: October 11, 2001Date of Patent: September 14, 2004Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gavril Pasternak, Yuri Kolesnikov
-
Patent number: 6784315Abstract: A Type IV crystal of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide hydrochloride, which can be produced by crystallization using a solvent containing water at 2% by weight at the maximum and which has a X ray powder diffraction pattern containing peaks at least at 13.4°, 18.7°, 19.4°, and 22.5° (2&thgr;), is provided. This compound is useful as an effective ingredient for a carcinostatic agent. The crystal of the present invention has excellent properties desirable from the standpoint of the production of medicinal products, i.e., reduced water adsorption and extremely high stability to water. Also provided are a method for producing the Type IV crystal thereof and a method for use of the crystal.Type: GrantFiled: September 16, 2002Date of Patent: August 31, 2004Assignee: Ajinomoto Co. Inc.Inventors: Shinichiro Takahashi, Yoko Sugawara, Hiroyuki Matsueda
-
Publication number: 20040143008Abstract: The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.Type: ApplicationFiled: October 14, 2003Publication date: July 22, 2004Inventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor
-
Patent number: 6762174Abstract: The present invention relates to peptide-like compounds, e.g. aminocarboxylic acid amide derivatives, and to methods of using same to stimulate cells of the immune system, bone marrow and other organs. The present compounds can be used to enhance vaccination, increase synthesis of and enhance function of blood cell components and enhance anti-neoplastic effects of various agents. The compounds of the invention can be used to produce a variety of further pharmacologic effects.Type: GrantFiled: February 24, 1999Date of Patent: July 13, 2004Assignee: Dovetail Technologies, Inc.Inventor: Floyd E. Taub
-
Publication number: 20040127569Abstract: Therapeutic methods for the prevention and treatment of conditions and diseases of the gastrointestinal tract involving an overproduction of nitric oxide by inducible nitric oxide synthase are described, the methods including administering to a subject in need thereof a therapeutically effective amount of a selective inhibitor of inducible nitric oxide synthase (iNOS). The methods also include the use of selective inhibitors of iNOS in combination with other therapeutic agents, including antimicrobial agents and antisecretory agents.Type: ApplicationFiled: July 25, 2003Publication date: July 1, 2004Inventors: Pamela T. Manning, Jane R. Connor
-
Publication number: 20040127426Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: June 24, 2003Publication date: July 1, 2004Applicant: AXYS PHARMACEUTICALS, INC.Inventors: Michael Graupe, John O. Link
-
Publication number: 20040110832Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.Type: ApplicationFiled: August 8, 2003Publication date: June 10, 2004Inventors: Adnan M.M. Mjalli, Robert C. Andrews, Xiao-Chuan Guo, Daniel Peter Christen, Devi Reddy Gohimmukkula, Guoxiang Huang, Robert Rothlein, Sameer Tyagi, Tripura Yaramasu, Christopher Behme
-
Publication number: 20040106560Abstract: 1Type: ApplicationFiled: November 20, 2003Publication date: June 3, 2004Inventors: Lars Eric Sundstrom, Fausto Iannotti, Mark Bradley, Ashley Ker Pringle
-
Patent number: 6734204Abstract: Analogs related to oleamide are employed for potentiating the 5-HT2A and 5-HT1A responses to serotonin (5-HT). With respect to the potentiation of the 5-HT2A receptor response, it is disclosed that, of the naturally occurring fatty acids, the primary amide of oleic acid (oleamide) is the most effective potentiating agent of serotonin and that the potentiating activity of oleamide analogs is highly dependent upon their structural features. In particular, the presence, position, and stereochemistry of the 9-cis double bond is required and even subtle structural variations reduce or eliminate activity. Secondary or tertiary amides may replace the primary amide but follow a well-defined relationship requiring small amide substituents suggesting that the carboxamide serves as a hydrogen bond acceptor but not donor. Alternative modifications at the carboxamide as well as modifications of the methyl terminus or the hydrocarbon region spanning the carboxamide and double bond typically eliminate activity.Type: GrantFiled: September 28, 2000Date of Patent: May 11, 2004Assignee: The Scripps Research InstituteInventor: Dale L. Boger
-
Patent number: 6730329Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.Type: GrantFiled: February 26, 2002Date of Patent: May 4, 2004Inventor: Jeffrey B. Smith
-
Publication number: 20040077639Abstract: Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.Type: ApplicationFiled: May 16, 2003Publication date: April 22, 2004Inventor: Pamela T. Manning
-
Patent number: 6716446Abstract: A local anesthetic is used for the manufacture of a medicament for use against dysmenorrhoea and premenstrual syndrome and for increasing fertility. A pharmaceutical composition may also be used that comprises a pharmaceutically effective dose of a local anesthetic together with a pharmaceutically acceptable excipient. The invention also relates to a process for using a catheter to pertubate the fallopian tubes to reduce dysmenorrhoea and premenstrual syndrome symptoms in a woman with the pharmaceutical composition that is intended to reach and exert an effect in the peritoneal cavity.Type: GrantFiled: August 2, 2002Date of Patent: April 6, 2004Assignee: Org. Nr. 556599-4968Inventor: Greta Edelstam
-
Patent number: 6716411Abstract: The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.Type: GrantFiled: December 13, 2000Date of Patent: April 6, 2004Assignee: Aventis Pharma Deustschland GmbHInventors: Jürgen Lindner, Burkhard Haase
-
Publication number: 20040039034Abstract: The present invention relates to compounds of formula (I): 1Type: ApplicationFiled: April 30, 2003Publication date: February 26, 2004Inventors: John A. Tucker, Brian A. Sherer, Ying Zi Xu, Louis Brogley, Shon R. Pulley, Jon S. Jacobs, James P. Beck, Varghese John
-
Patent number: 6685953Abstract: The present invention relates to a dermatologic preparation containing a diamide derivative represented by the following formula (1): (wherein, R1 represents a linear or branched hydrocarbon group having 1 to 22 carbon atoms which may be substituted by one or more hydroxy and/or alkoxy groups, R2 represents a linear or branched divalent hydrocarbon group having 1 to 12 carbon atoms, and R3 represents a linear or branched divalent hydrocarbon group having 1 to 42 carbon atoms). This diamide derivative (1) is capable of fundamentally improving the water retention capacity and barrier functions of the horny layer, is excellent in miscibility and mixing stability and can be prepared efficiently at a low cost.Type: GrantFiled: October 4, 2001Date of Patent: February 3, 2004Assignee: Kao CorporationInventors: Masahide Hoshino, Yoshiya Sugai, Akiyo Kameyama, Hiroaki Saito, Yoshinori Nishizawa, Yutaka Takagi
-
Publication number: 20040019086Abstract: The present invention relates to compounds of formula (I): 1Type: ApplicationFiled: July 10, 2002Publication date: January 29, 2004Inventors: Heinrich Josef Schostarez, Robert Alan Chrusciel
-
Publication number: 20040018987Abstract: The invention provides methods and compositions for treatment of tumors comprising administering to subject bearing a tumor an effective amount of at least one agent that decreases the [GSH]2/[GSSG] ratio in the malignant cells of said tumor, wherein said at least one agent is administered continuously to said patient for a period of time within the range of from about 15 to about 75 hours.Type: ApplicationFiled: July 18, 2003Publication date: January 29, 2004Inventors: Arnold Hoffman, Lee M. Spetner, Michael Burke
-
Patent number: 6677376Abstract: The invention relates to non-peptidic compounds that possess bioactive properties, such as the ability to protect neuronal cells from otherwise lethal treatments or the ability to promote the growth or regeneration of neuronal cells. In part, the invention provides compounds that interact with or bind to a cyclophilin and compounds that have activity towards neuronal cells. Methods for using the compounds, such as administering them to cells or animals or using them to treat neurodegenerative conditions, are specifically included.Type: GrantFiled: September 7, 2000Date of Patent: January 13, 2004Assignee: Guilford Pharmaceuticals, Inc.Inventors: Gregory S. Hamilton, Joseph P. Steiner, Mark J. Vaal, Chi Choi, Ling Wei
-
Publication number: 20030229141Abstract: Methods to alleviate or improve various cosmetic conditions and dermatological disorders, including changes or damage to skin, nail and hair associated with intrinsic aging and/or extrinsic aging, as well as changes or damage caused by extrinsic factors using compositions comprising N-acetyl-cysteine (isomeric or non-isomeric forms) and/or free acid, salt, lactone, amide or ester forms of N-acetyl-cysteine are described. The methods provided may also comprise application of a composition further containing various cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.Type: ApplicationFiled: June 17, 2003Publication date: December 11, 2003Inventors: Ruey J. Yu, Eugene J. Van Scott
-
Publication number: 20030225087Abstract: The present invention provides novel N-alkyl-N-phenylhydroxylamine derivatives containing metal chelating groups, a process for preparing the same, the use of the novel compounds as therapeutics for treating and/or preventing various medical dysfunctions and diseases arising from reactive oxygen species (ROS) and/or excess Zn ions, in particular stroke, Parkinson's disease and Alzheimer's disease. The compounds of the invention possess similar or superior LPO inhibition activity to the reference compounds of Trolox and Ebselen. While showing lower toxicity, they also effectively inhibit the cerebral neuronal cell death caused by ROS and/or zinc ion, and show neuroprotective effects against ischemic neuronal degeneration.Type: ApplicationFiled: June 5, 2003Publication date: December 4, 2003Inventors: Eu-Gene Oh, Sung-Bo Ko, Won-Yeob Kim, Kyung-Hwa Kim, Dennis W. Choi, Laura L. Dugan, Tae-Cheon Kang, Jae-Young Koh, Kyung-Mi Kim, In-Jae Shin
-
Publication number: 20030220350Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.Type: ApplicationFiled: August 30, 2002Publication date: November 27, 2003Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Thoger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thogersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jogensen, Janos Tibor Kodra, Shenghua Shi
-
Patent number: 6653299Abstract: A complex of a radiometal or paramagnetic metal ion with a metal chelating agent such as a diaminedioxime has attached thereto a substituent of formula —(Y)m—A—NHR, can function as a substrate for the fibrin-stabilizing Factor XIIIa. The complex is useful for the diagnosis or therapy of thrombosis, embolism, atherosclerosis, inflammation or cancer.Type: GrantFiled: October 4, 1999Date of Patent: November 25, 2003Assignee: Nycomed Amersham PLCInventors: Alan Michael Forster, Peter Knox, Marivi Mendizabal, Timothy Charles Richardson, Anthony Eamon Storey, Ian Andrew Wilson, Susan Champion, Alex Gibson, Benedicte Guilbert
-
Publication number: 20030203055Abstract: The present invention provides a method of treating a visceral pain syndromes in a mammal. The method includes administering to the mammal an effective amount of a selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI), e.g., milnacipran.Type: ApplicationFiled: March 17, 2003Publication date: October 30, 2003Applicant: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Jay D. Kranzler
-
Publication number: 20030195227Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.Type: ApplicationFiled: September 18, 2002Publication date: October 16, 2003Applicant: Monsanto CompanyInventors: John J. Talley, Daniel P. Getman, Gary A. DeCrescenzo, Kathryn L. Reed, Ko-Chung Lin, John Nicholas Freskos, Michael Clare, Donald Joseph Rogier, Robert M. Heintz, Michael L. Vazquez, Richard A. Mueller
-
Patent number: 6620845Abstract: The present invention provides novel aminoadamantane derivatives, methods of making the derivatives, compositions including the novel aminoadamantane derivatives, and methods for the treatment and prevention of neurological diseases using the derivatives and compositions.Type: GrantFiled: July 19, 2002Date of Patent: September 16, 2003Assignee: NeuroMolecular, Inc.Inventors: Yuqiang Wang, Wenqing Ye, James W. Larrick, Jonathan S. Stemler, Stuart A. Lipton
-
Patent number: 6620852Abstract: The present invention is directed to an improved flowable anesthetic composition that does not need to be applied by an applicator. The anesthetic composition of the present invention may be applied by dripping or spraying the composition onto a wound or other injured area. The composition of the anesthetic includes one or more anesthetics, and a base comprising a surgical lubricant. If desired, the composition may also include one or more vasoconstrictors. The vasoconstrictor is preferably an adrenaline based compound and more preferably epinephrine. The surgical lubricant is preferably water soluble. The anesthetics may include any of the well-known anesthetics such as lidocaine, pontocaine, tetracaine, bupivicaine, procaine and others.Type: GrantFiled: December 17, 2001Date of Patent: September 16, 2003Inventors: Gerald Brogan, Joel Karen, Richard Malerba
-
Publication number: 20030149092Abstract: A novel compound with anthraquinone structure and having the following foluma (I): 1Type: ApplicationFiled: December 20, 2001Publication date: August 7, 2003Applicant: Industrial Technology Research InstituteInventors: Lain-Tze Lee, jinun-Ban Yeh
-
Publication number: 20030144253Abstract: The present invention relates to acyclic and cyclic amine derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.Type: ApplicationFiled: January 30, 2002Publication date: July 31, 2003Inventors: Michael Mullican, David Lauffer, Roger Tung
-
Patent number: 6589992Abstract: The present invention describes a therapeutic method useful for treating or preventing a condition of platelet aggregation in a subject including administering to the subject a pharmaceutically effective amount of a compound or composition that inhibits BTK and collagen-induced platelet aggregation. The condition of platelet aggregation includes cardiovascular, hematopoietic and cerebrovascular diseases.Type: GrantFiled: February 15, 2002Date of Patent: July 8, 2003Assignee: Parker Hughes InstituteInventor: Fatih M. Uckun
-
Publication number: 20030119826Abstract: Therapeutic methods for the prevention and treatment of neurodegenerative conditions are described, the methods including administering to a subject in need thereof a neuroprotective effective amount of a selective inhibitor of inducible nitric oxide synthase.Type: ApplicationFiled: September 24, 2001Publication date: June 26, 2003Applicant: Pharmacia CorporationInventors: Pamela T. Manning, Jane R. Connor
-
Publication number: 20030119803Abstract: A compound selected from the group consisting of a compound of formula I 1Type: ApplicationFiled: September 17, 2002Publication date: June 26, 2003Inventors: Brent Richard Stranix, Gilles Sauve, Abderrahim Bouzide, Alexandre Cote, Gervais Berube, Patrick Soucy, Yongsen Zhao, Jocelyn Yelle
-
Publication number: 20030109522Abstract: Therapeutic methods for the prevention and treatment of ophthalmologic conditions are described, the methods including administering to a subject in need thereof a selective inhibitor of inducible nitric oxide synthase.Type: ApplicationFiled: September 24, 2001Publication date: June 12, 2003Inventors: Pamela T. Manning, Jane R. Connor
-
Patent number: 6576679Abstract: A hydrogel formed by adding an anion having a molecular weight of 90 or more to an aqueous dispersion of a cationic amphiphile comprising a linear or branched alkyl group having 10 or less carbon atoms in a hydrophobic moiety. The hydrogel has a network having a bilayer-membrane, nano-fiber structure and undergoes a reversible gel-sol transformation.Type: GrantFiled: September 18, 2001Date of Patent: June 10, 2003Assignees: Honda Giken Kogyo Kabushiki Kaisha, Nobuo KimizukaInventors: Nobuo Kimizuka, Takuya Nakashima, Kazuhiro Kagawa
-
Publication number: 20030083356Abstract: The present invention relates to compounds of formula (I): 1Type: ApplicationFiled: July 10, 2002Publication date: May 1, 2003Inventors: Heinrich Josef Schostarez, Robert Alan Chrusciel
-
Patent number: RE38761Abstract: A method of inhibiting cell proliferation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition comprising, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, which is a substituted styrene compound which can also be a naphthalene, an indane or a benzoxazine; including nitrile and molononitrile compounds, and pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically-effective amount of such compound.Type: GrantFiled: October 14, 1994Date of Patent: July 19, 2005Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Alexander Levitzki, Chaim Gilon, Michael Chorev, Aviv Gazit